

NDA 21-075

Genentech, Inc.
Attention: Robert L. Garnick, Ph.D.
Vice President, Regulatory Affairs
1 DNA Way
South San Francisco, CA 94080-4990

Dear Dr. Garnick:

Please refer to your new drug application (NDA) dated June 25, 1999, received June 28, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Nutropin Depot (somatropin [rDNA origin] for injectable suspension), 13.5mg, 18.0mg, and 22.5 mg.

We acknowledge receipt of your submissions dated August 11 and 13, September 20, October 8 and 22, November 30, and December 10 and 14, 1999.

This new drug application provides for the use of Nutropin Depot (somatropin [rDNA origin] for injectable suspension) for the long-term treatment of growth failure due to a lack of adequate endogenous GH secretion for once- or twice-a-month administration.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text and with the following minor editorial revision: the established name shall be in type at least half as large as the type used for the proprietary name. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical, and include the minor editorial revisions indicated, to the submitted draft labeling (package insert submitted December 14, 1999, patient package insert submitted December 10, 1999, immediate container and carton labels submitted December 10, 1999). These revisions are terms of the NDA approval. Marketing the product before making the revisions, exactly as requested, in the product's final printed labeling (FPL) may render the product misbranded and an unapproved new drug.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved NDA 21-075." Approval of this submission by FDA is not required before the labeling is used.

We remind you of your Phase 4 commitment specified in your submission dated December 14, 1999. Genentech commits to continue to work on development of an [] that will provide

a profile of the []. A revised specification for either this [] will be submitted within one year of the date of this letter. This specification will include [].

Protocols, data, and final reports should be submitted to your IND for this product and a copy of the cover letter sent to this NDA. If an IND is not required to meet your Phase 4 commitments, please submit protocols, data and final reports to this NDA as correspondence. In addition, under 21 CFR 314.82(b)(2)(vii), we request that you include a status summary of each commitment in your annual report to this NDA. The status summary should include the number of patients entered in each study, expected completion and submission dates, and any changes in plans since the last annual report. For administrative purposes, all submissions, including labeling supplements, relating to these Phase 4 commitments must be clearly designated "Phase 4 Commitments."

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 *FR* 66632). We note that you have fulfilled the pediatric study requirement at this time.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Crystal King, P.D., M.G.A., Regulatory Project Manager, at (301) 827-6423.

Sincerely yours,

Solomon Sobel, M.D.
Director
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research